Private equity activity in Japan’s healthcare sector continues to accelerate, driven by strong capital inflows, ageing demographics, and growing opportunities in digital health and senior-care services.
Eli Lilly has increased their UK price for the weight-loss injection Mounjaro by 170% to align with prices in other high-income countries. This move follows Trump’s mandate on pharmaceuticals to raise prices abroad to make them more affordable for U.S. consumers.
Investor interest is surging in women’s health tech, with wearables like Oura Ring and Whoop attracting hundreds of millions in funding. These devices give personalised insights into menstrual, reproductive, and menopausal health, highlighting a rapidly expanding market long overlooked by traditional healthcare.
Alcon’s planned purchase of STAAR Surgical adds the latter’s EVO ICL lens technology to its refractive surgery portfolio, aiming to broaden treatment options for myopia and strengthen its position in a market seeing significant deal activity.
The growing demand for integrated, personalised weight management solutions presents a major opportunity for hybrid care models that combine digital health programmes with in-person dietitian consultations.
Despite upcoming profit caps and tighter regulations, France’s medical laboratory sector remains large and resilient. It still offers opportunities for investors in regional and tech-driven labs able to navigate tighter margins.
UK healthcare real estate investor Assura has voted to accept a bid from Primary Health Properties (PHP), the only other UK REIT with a significant primary care portfolio. The decision brings an end to a takeover contest with US private equity firm KKR.
With France facing persistent medicine shortages and heightened political focus on healthcare sovereignty, the generic pharmaceuticals sector is drawing increased attention from private investors and policymakers alike. Growing interest in maintaining domestic production and securing supply chains has positioned French generics as both a strategic asset and a market opportunity.
Last month, HBI covered how EU tariff negotiations would affect pharma prices. At that time, Donald Trump had been threatening a 50% tariff on all EU imports and a 200% tariff on pharmaceutical imports, creating much uncertainty around the final state of the trade deal. On Tuesday, however, Trump told CNBC that while the tariffs on pharmaceuticals may be “small” initially, in a year's time they will be increased to 150% and then 250%.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
